ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19
Quotient and ANA Therapeutics announce partnership to develop drug candidate, ANA001 (niclosamide capsules) as a potential treatment for COVID-19.
Quotient Sciences Completes Million Dollar Pharmacy Expansion at Miami Clinic
State-of-the-Art Compounding Pharmacy Will Accelerate Early Development Programs
Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials announced by Quotient Sciences and CytoAgents.
Coronavirus (COVID-19) Statement Update
We are confronting an unprecedented crisis caused by the COVID-19 viral outbreak. Inevitably this pandemic will result in significant impact on society and interruption to businesses. None of us have experienced anything equivalent to this situation, and it is changing rapidly on a day-to-day basis.
Coronavirus (COVID-19) Statement - 17/03/2020
As a leading business in the healthcare industry, we understand the gravity of the situation and the challenge ahead of us. The management of Quotient Sciences has been closely monitoring the ongoing COVID-19 situation and taking steps to limit any potential impact it could have on our trial subjects, our staff, our customers, our community, and our business.
Quotient Sciences, University of Nottingham, AstraZeneca and Added Scientific Ltd receive MRC grant to advance 3D printing of solid dosage forms
The Faculty of Engineering and School of Pharmacy, at the University of Nottingham, are delighted to announce the receipt of an MRC Confidence in Concepts grant. Working in collaboration with Quotient Sciences, Added Scientific and AstraZeneca, the grant will translate towards clinical applications some of the advances made at Nottingham in the 3D printing of pharmaceutical dosage forms.